Jonathan Silverberg, MD, PhD, MPH

Dr. Silverberg is a Professor of Dermatology at the George Washington University School of Medicine and Health Sciences

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

Join the Revolution next month in Nashville. You can register for FREE using the code: Silverberg at checkout

#PER #eczema #dermatology

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

Join me in Music City June 6–7 for the Revolutionizing #AtopicDermatitis conference! Immerse in Nashville’s unique charm. Earn CME over two days of cutting-edge derm education. Use Silverberg at checkout for free registration https://t.co/LWq52tEXeg #RAD2025 #gotoper

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

The Revolutionizing Atopic Dermatitis Conference in in Nashville, TN on June 6–7 this year! Join me and leading experts for two days of learning, networking, and AD insights. Use my code Silverberg for free registration! https://t.co/LWq52tEXeg #RAD2025 #AtopicDermatitis #gotoper

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

Thrilled to share that Dr. Chovatiya will be joining me at Revolutionizing Atopic Dermatitis (RAD) on June 6-7 in Nashville, TN!

Use my code Silverberg for free registration and save your spot now: https://t.co/P2zPRRICbf

#RAD #AtopicDermatitis #gotoper

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

Join me at Revolutionizing Atopic Dermatitis (RAD) on June 6-7 in Nashville, TN! We will be discussing groundbreaking concepts in AD—where medicine meets Nashville’s rhythm.

Use my code Silverberg for free registration: https://t.co/P2zPRRICbf

#RAD #AtopicDermatitis #gotoper

[Revolutionizing AD @RevAtopicDerm]

You’re invited to the December virtual update on Revolutionizing Atopic Dermatitis! Get ready for CME/CE with practical patient-centered conversations and presentations on late-breaking research. Join us on December 8: https://t.co/LuB6qNP5rm @JonathanMd , @RajMDPhD

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

Check out this study of the validity of ICD10 codes for identifying #atopicdermatitis in health services research. You can learn more about these results at the @RevAtopicDerm conference on December 11th.

https://t.co/VuJJeIY5GB

#eczema #dermtwitter #allergy #dermatology

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

New Directions in Atopic Dermatitis Management: Harnessing the Power of Social Learning to Improve Patient Outcomes https://t.co/S2oB8g49TD

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

Stay tuned for more programs.

[@derm_ce @derm_ce]

33) And that's it! You just earned 0.5h CE/#CME just by following this 🧵. Accredited education on Twitter! What a concept! I am @JonathanMd inviting you to FOLLOW @derm_ce for more #tweetorials in #dermatology from expert authors.
#dermtwitter #FOAMed @derminterest @DermNPPA

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

It is an exciting time in #dermatology.

[@derm_ce @derm_ce]

32) It appears that #topical application avoids the rare #toxicity seen with #systemic administration of #JAK-inhibitors. #AD is a pervasive problem in kids & adults and it's great to envision new, targeted, effective therapies!

[@derm_ce @derm_ce]

31) There is growing evidence that JAK inhibitors are efficacious in #atopic_dermatitis, #alopecia_areata, #psoriasis, & #vitiligo. Additional evidence suggests that JAK inhibition may be broadly useful in dermatology, with early reports of efficacy in several other conditions.

[@derm_ce @derm_ce]

29) Studies in Japanese adults with #AD of #topical #delgocitinib 0.5% ointment have been promising. See 🔓https://t.co/lu905lZfLp

[@derm_ce @derm_ce]

25b) Significant itch reductions versus vehicle were reported within 12 hours of first application of 1.5% RUX (P < .05). Application site reactions were infrequent (<1%) and lower with RUX versus vehicle; none were clinically significant.

[@derm_ce @derm_ce]

24a) Indeed, there are 2⃣: Topical #Ruxolitinib Evaluation in #Atopic_Dermatitis Study 1 (NCT03745638) & Study 2 (NCT03745651) #TRuE_AD enrolled patients aged ≥12 yrs with AD for ≥2 yrs, an Investigator's Global Assessment score of 2/3, and 3%-20% affected body surface area.

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

Welcome back everyone! If you missed yesterday's posts, all you have to do is scroll up. Enjoy!

[@derm_ce @derm_ce]

21) Welcome back! I am @JonathanMd and we are all about #topical #JAK inhibitors for atopic dermatitis #AD on your ONLY source for CE/#CME #accredited #tweetorials in #dermatology. Your link to your 🆓credit is at the end of this 🧵!
👏@eczemasociety @nationaleczema

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

See you back here tomorrow

[@derm_ce @derm_ce]

20) Show us what you learned by marking your best answer. Correct responses--and your link to 🆓CE/#CME to follow when we see you here tomorrow. 👍to @DrCandriceHeath @nationaleczema @DrJanPeds @aaron_drucker @JosephMerolaMD @paller_lab @Dr_BaderAlOmair @DrJoelGelfand

[Jonathan Silverberg, MD, PhD, MPH @JonathanMd]

See how much you know about JAK-inhibition in AD

[@derm_ce @derm_ce]

19) Follow-on Ph 3 studies yielded similar results. We'll address those TOMORROW and also talk about potential emerging topical #JAK inhibitors still to come. Meanwhile, which JAK receptor/s does #ruxolitinib inhibit?

[@derm_ce @derm_ce]

10a) Thus #JAK inhibition can block the effects of multiple cytokines that are major players in #AD pathophysiology & ⬇️symptomatology. As per previous expert tweetorials from @DrStevenTChen @itchdoctor @Aller_MD (still available for CE/#CME credit at https://t.co/Pe6utbwPkZ)...

[@derm_ce @derm_ce]

9) The #JAK-#STAT signaling pathway mediates effects of several key #cytokines on immune cells, keratinocytes, and peripheral sensory neurons that lead to inflammation and itch, including IL-4, IL-5, IL-13, IL31, IL-22, and TSLP
See https://t.co/kgmAkm9DMO.